5591 results
Refine Your Search
Yoke Seng Lee
My scientific background involves the functional characterization of rare immune cells called dendritic cells in advanced melanoma patients. These cel…
Patrizia Mondello
I am a focusing on the biology and therapeutic targeting of lymphoma. I trained in Medical Oncology in Italy. Given my interest in the molecular mec…
Jianguo Tao
I am a trained clinical hematopathologist and who is well versed in both basic and translational studies in hematologic tumors, with a special intere…
Understanding Resistance Mechanism to Enhance CAR-T Immunotherapy for MCL
Mantle cell lymphoma (MCL) is an aggressive lymphoma characterized by resistance to standard treatments and short survival. For the LLS MCLII Synerg…
Lawrence Boise
Lawrence Boise, PhD is the R. Randall Rollins Chair of Oncology and Professor in the Department of Hematology and Medical Oncology in the Emory Univer…
Functional dissection of heterogeneity of responses to CAR T cells using Spatiotemporal Image-guided Genomic and Cellular Analysis (SaGA) in myeloma
Despite remarkable progress in the last years, multiple myeloma remains an incurable disease. In recent years, CAR T cell products that target BCMA …
Exploiting tumor-immune dynamics to inform curative combination therapy for follicular lymphoma
Follicular lymphoma is a common form of blood cancer, affecting , new patients annually in the United States, but it remains incurable with convention…
Mark Murakami
Dr. Mark Murakami is a dedicated to advancing curative treatments for follicular lymphoma. Based in the Division of Hematologic Neoplasia at the Can…
Bing Carter
Dr. Carter, a Professor in the Section of Molecular Hematology and Therapy, Department of Leukemia has + years of experience in molecular biology, bio…
Targeting TP53-Y220C mutant AML
TP53-Y220C is a recurrent hotspot TP53 mutation observed predominantly in AML and MDS among hematological malignancies. This study aims to investigate…
Toward improvement of BCMA/CST6-CAR-T therapy to target both myeloma cells and bone resorption
We have observed that CST6 proteins suppress osteoclast differentiation and function without causing immunosuppression. We aim to determine whether …
Research: Grants
Fenghuang Zhan
Fenghuang (Frank) Zhan, MD & PhD, is a Professor of Medicine and the Research Director of Myeloma Center at University of Arkansas for Medical Science…
Nicola Vannini
Nicola Vannini after his MSc degree in Biological Sciences obtained at the University of Parma, moved to La Jolla (CA) where he worked for two years a…
Mitochondrial reprogramming to restore age-driven dysfunction in T cell and boost CAR-T cell therapy
In the Cancer Immunology field, the “aging” variable has not been investigated profoundly yet, even though aging is the first factor associated to can…
Jake Shortt
Professor Jake Shortt is a clinician scientist who is by Monash Health as Director of Clinical Haematology and by Monash University as the Head of Ha…
Targeting metabolic reprogramming in MDS and AML stem/progenitor cells
Myelodysplastic neoplasms are malignant disorders driven by expansion of diseased hematopoietic stem cells and progression to leukemia. Our investigat…
Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma
As a lymphoma develops it expresses genes that are normally silenced to convey a survival advantage. When these genes are on the X or Y (sex chromosom…
Paul Beavis
I am an Assoc. Prof. and Group Leader at the Peter MacCallum Cancer Centre (Peter Mac; Melbourne, Australia).
Enhancing the “fitness” of anti-BCMA CAR T cells for improved efficacy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy is a form of therapy where a patient’s own immune cells are genetically engineered to recognize and ki…
A phase 2 study of Bexmarilimab, an anti-Clever1 monoclonal antibody, in combination with azacitidine in patients with high-risk MDS
In June , LLS made an equity investment in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indications…
Functionalizing novel PHIP variants in ancestry-specific acute myeloid leukemia
AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of Black AML pa…
Bailee Kain
Dr. Bailee Kain is from Geneseo, IL and received her B.S. in Biochemistry from University of Missouri in . She completed her doctoral thesis work at B…
Nataly Cruz-Rodriguez
I am a Research Scientist in the Deininger Lab at Versiti Blood Research Institute, where my work focuses on leukemia biology—particularly in hematopo…
Understanding the role of Metabolic Regulator SIRT5 in Acute Lymphoblastic Leukemia
p>SIRT5 is a master regulator of central energy metabolism. The survival and growth of Acute Myeloid Leukemia (AML) cells depend on SIRT5. I will e…
Research: Grants
Bingyi Chen
I am a Research Scholar in the laboratory of Dr. Omar at Memorial Sloan Kettering Cancer Center.